ANTIVIRAL RESPONSE OF DRUGS USED AGAINST HBV PATIENTS OF KHYBER PAKHTUNKHWA, PAKISTAN

N HASSAN; FU AMIN; K BASHIR; M IRSHAD; S JAMIL; N MUNAWAR; H HAQQANI; H SHABIR; MA KHAN

doi:10.54112/bbasr.v2023i1.49

Authors

N HASSAN Department of Health and Biological Science, Abasyn University Peshawar, KP Pakistan
FU AMIN Department of Health and Biological Science, Abasyn University Peshawar, KP Pakistan/Division of Life Science, Center for Cancer Research and State Key Lab for Molecular Neuroscience, Hong Kong University of Science and Technology
K BASHIR Department of Health and Biological Science, Abasyn University Peshawar, KP Pakistan
M IRSHAD Department of Health and Biological Science, Abasyn University Peshawar, KP Pakistan
S JAMIL Department of Health and Biological Science, Abasyn University Peshawar, KP Pakistan
N MUNAWAR Department of Health and Biological Science, Abasyn University Peshawar, KP Pakistan
H HAQQANI Department of Health and Biological Science, Abasyn University Peshawar, KP Pakistan
H SHABIR Department of Health and Biological Science, Abasyn University Peshawar, KP Pakistan
MA KHAN Department of Medicine, Khyber Medical college, Peshawar Khyber Pakhtunkhwa, Pakistan

DOI:

https://doi.org/10.54112/bbasr.v2023i1.49

Keywords:

Hepatitis B virus, Entecavir, Tenofovir, Bilirubin, Creatinine, ALT

Abstract

Hepatitis B virus is an ample cause of end-stage liver diseases and hepatocellular carcinoma. Effective treatment in high-risk countries such as Pakistan can help delay or prevent these consequences.The existing study aims to evaluate the response rates of antiviral drugs tenofovir and entecavir (6-48 months) based on different clinical parameters. Sera collected from HBV patients (43) subjected to DNA extraction, followed by real-time PCR detection. Furthermore, ICT was performed to detect HBs-Ag and ELISA for HBe-Ag. Response rate after 6 months of tenofovir treatments showed 100% normal creatinine and ultrasound and ALT (50%) and while in the case of entecavir, each ALT and ultrasound normalization (66.7%), showed creatinine (100%). The fatty liver was reported 50% and 33.3% after tenofovir and entecavir treatment, respectively. The response after 12 months of treatment with tenofovir showed normalization of ALT and ultrasound (84.6%), bilirubin and creatinine normalization (92.3%), and fatty liver (15.4%). Whereas bilirubin and creatinine levels showed (100%) normal, ALT and ultrasound normalization (80%) with 20% of patients having congenital left lobe of the liver after entecavir. Patients profiles after 24 months of tenofovir treatment showed normal ALT and ultrasound (85.7%), bilirubin (100%), and renal impairment observed in patients (14.3%). The 24 months entecavir treatment showed significant improvement in various clinical parameters normalization with 100% such as ALT, bilirubin, and creatinine in all patients. The efficacy of entecavir showed a significant response as compared to Tenofovir. Furthermore, nucleoside/nucleotide analogues enhanced its efficacy with longer treatment duration.

References

But, D. Y.-K., Yuen, M.-F., Fung, J., and Lai, C.-L. (2010). Safety evaluation of telbivudine. Expert Opinion on Drug Safety 9, 821-829. DOI: 10.1517/14740338.2010.507190 DOI: https://doi.org/10.1517/14740338.2010.507190

Chang, T.-T., and Suh, D. J. (2008). Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatology International 2, 19-27. DOI: 10.1007/s12072-008-9059-0 DOI: https://doi.org/10.1007/s12072-008-9059-0

Clercq, E. D., Férir, G., Kaptein, S., and Neyts, J. (2010). Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses 2, 1279-1305. DOI: 10.3390/v2061279 DOI: https://doi.org/10.3390/v2061279

Cooke, G. S., Main, J., and Thursz, M. R. (2010). Treatment for hepatitis B. Bmj 340. DOI: 10.1136/bmj.b5429 DOI: https://doi.org/10.1136/bmj.b5429

Cornberg, M., Wong, V. W.-S., Locarnini, S., Brunetto, M., Janssen, H. L., and Chan, H. L.-Y. (2017). The role of quantitative hepatitis B surface antigen revisited. Journal of hepatology 66, 398-411. DOI:10.1016/j.jhep.2016.08.009 DOI: https://doi.org/10.1016/j.jhep.2016.08.009

Kalim, M., Imran, M., Hussain, F., Khan, I. U., Habib, N., Iqbal, M. N., and Ashraf, A. (2017). Detection of HBV and HCV by ICT and ELISA Method in Different Areas of District Malakand. PSM Microbiology 2, 5-8. https://core.ac.uk/download/pdf/327166117.pdf

Lai, C.-L., and Yuen, M.-F. (2008). Chronic hepatitis B-new goals, new treatment. New England Journal of Medicine. DOI: 10.1056/NEJMe0808185 DOI: https://doi.org/10.1056/NEJMe0808185

Liaw, Y.-F., and Chu, C.-M. (2009). Hepatitis B virus infection. The lancet 373, 582-592. DOI: 10.1016/S0140-6736(09)60207-5 DOI: https://doi.org/10.1016/S0140-6736(09)60207-5

Lok, A. S., Zoulim, F., Dusheiko, G., and Ghany, M. G. (2017). Hepatitis B cure: from discovery to regulatory approval. Journal of hepatology 67, 847-861. DOI: 10.1016/j.jhep.2017.05.008 DOI: https://doi.org/10.1016/j.jhep.2017.05.008

Manzoor, S., Idrees, M., Ashraf, J., Mehmood, A., Butt, S., Fatima, K., Akbar, H., Rehaman, I. U., and Qadri, I. (2011). Identification of ionotrophic purinergic receptors in Huh-7 cells and their response towards structural proteins of HCV genotype 3a. Virology Journal 8, 1-5. DOI: 10.1186/1743-422X-8-431 DOI: https://doi.org/10.1186/1743-422X-8-431

Ott, J., Stevens, G., Groeger, J., and Wiersma, S. (2012). Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212-2219. DOI:10.1016/j.vaccine.2011.12.116 DOI: https://doi.org/10.1016/j.vaccine.2011.12.116

Pei, Y., Wang, C., Yan, S. F., and Liu, G. (2017). Past, current, and future developments of therapeutic agents for treatment of chronic hepatitis B virus infection. Journal of medicinal chemistry 60, 6461-6479. DOI:10.1021/acs.jmedchem.6b01442 DOI: https://doi.org/10.1021/acs.jmedchem.6b01442

Seeger, C., and Mason, W. S. (2015). Molecular biology of hepatitis B virus infection. Virology 479, 672-686. DOI:10.1016/j.virol.2015.02.031 DOI: https://doi.org/10.1016/j.virol.2015.02.031

Terrault, N. A., Bzowej, N. H., Chang, K. M., Hwang, J. P., Jonas, M. M., and Murad, M. H. (2016). AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63, 261-283. DOI: 10.1002/hep.28156 DOI: https://doi.org/10.1002/hep.28156

Terrault, N. A., Lok, A. S., McMahon, B. J., Chang, K. M., Hwang, J. P., Jonas, M. M., Brown Jr, R. S., Bzowej, N. H., and Wong, J. B. (2018). Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560-1599. DOI: 10.1002/hep.29800 DOI: https://doi.org/10.1002/hep.29800

Toka, B., Koksal, A. S., İskender, G., Çakmak, E., Üsküdar, O., Sezikli, M., Şirin, G., Yildirim, A. E., Fidan, S., and Acar, Ş. (2020). HBV flare associated with immunosuppressive treatments: it is still dangerous in the third-generation antivirals era. Antiviral therapy 25, 121-129. DOI: 10.3851/IMP3356 DOI: https://doi.org/10.3851/IMP3356

Wang, X.-Y., and Chen, H.-S. (2014). Emerging antivirals for the treatment of hepatitis B. World journal of gastroenterology: WJG 20, 7707. DOI: 10.3748/wjg.v20.i24.7707 DOI: https://doi.org/10.3748/wjg.v20.i24.7707

Wu, Y.-L., Shen, C.-L., and Chen, X.-Y. (2019). Antiviral treatment for chronic hepatitis B: safety, effectiveness, and prognosis. World journal of clinical cases 7, 1784. DOI: 10.12998/wjcc.v7.i14.1784 DOI: https://doi.org/10.12998/wjcc.v7.i14.1784

Xu, X.-H., Li, G.-L., Qin, Y., Li, Q., He, F.-Q., Li, J.-Y., Pan, Q.-R., and Deng, J.-Y. (2013). Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice. Virology journal 10, 1-5. DOI: 10.1186/1743-422X-10-162 DOI: https://doi.org/10.1186/1743-422X-10-162

Yang, R., Song, G., Guan, W., Wang, Q., Liu, Y., and Wei, L. (2016). The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen. Journal of virological methods 228, 39-47. DOI: 10.1016/j.jviromet.2015.11.016 DOI: https://doi.org/10.1016/j.jviromet.2015.11.016